Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13661142 | 0.98 | KDM4E (0.55) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL7326389 | 0.98 | KDM4E (0.55) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL28193913 | 0.98 | ALDH1A1 (0.54) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL25414330 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL21348666 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL26941949 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL18995674 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL13661139 | 0.94 | KDM4E (0.52) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL13644364 | 0.94 | ALDH1A1 (0.53) | KDM4EALDH1A1TSHRCARM1PRMT6 | |
| SCHEMBL13160710 | 0.92 | HRH3 (0.54) | KDM4EALDH1A1TSHRCARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-B1 | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009131246-A1 | SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| EP-1743885-A2 | TNF-Alpha Produktion Hemmer zur Behandlung von Autoimmunerkrankungen | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | KDM4E 1897/4885ALDH1A1 557/4885TSHR 153/4885 |
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | KDM4E 2747/4885ALDH1A1 950/4885TSHR 44/4885 |
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | KDM4E 223/4885ALDH1A1 1032/4885TSHR 4097/4885 |
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | KDM4E 2716/4885ALDH1A1 964/4885TSHR 72/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | KDM4E 223/4885ALDH1A1 1032/4885TSHR 4097/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | KDM4E 1375/4885ALDH1A1 1014/4885TSHR 498/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | KDM4E 1368/4885ALDH1A1 1011/4885TSHR 536/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | KDM4E 3050/4885ALDH1A1 556/4885TSHR 143/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | KDM4E 4050/4885ALDH1A1 1792/4885TSHR 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.